Abstract
Copyright: © 2014 Sofi AA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Increasing incidence of Clostridium difficile infection (CDI) and emergence of new and more virulent, antibiotic resistant strains such as 027 ribotype (NAP1/B1/027) [1] has been associated with an increased incidence of recurrences and primary treatment failure with standard antibiotic therapy [2]. Fecal microbiota transplantation (FMT) has shown promise in the treatment of recurrent or refractory CDI [3,4]. FMT involves instillation of stools obtained from a healthy donor into the recipient gut either by upper gastrointestinal (GI) route through naso-gastric tube or through lower GI route administered during colonoscopy or rectal enemas. There are no controlled studies comparing the efficacy and safety of upper and lower GI routes of FMT delivery in the treatment of CDI. In the absence of such studies, the preferable method of FMT administration is unknown.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of Gastrointestinal & Digestive System
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
